These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 29420119)
21. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703 [TBL] [Abstract][Full Text] [Related]
22. Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review. Harder T; Koch J; Wichmann O; Hellenbrand W J Infect; 2017 Aug; 75(2):81-94. PubMed ID: 28487177 [TBL] [Abstract][Full Text] [Related]
23. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Noronha CP; Struchiner CJ; Halloran ME Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439 [TBL] [Abstract][Full Text] [Related]
24. Biodistribution of the Cuban anti-meningococcal vaccine, VA-MENGOC-BC, in Balb/c mice. Pérez-Martín O; Lastre-González M; Díaz-Orellana M; Zayas-Vignier C; Caso R; Hernández I; Sierra-González G Arch Med Res; 1997; 28(1):37-40. PubMed ID: 9078585 [TBL] [Abstract][Full Text] [Related]
25. The epidemiological impact of antimeningococcal B vaccination in Cuba. Rodriguez AP; Dickinson F; Baly A; Martinez R Mem Inst Oswaldo Cruz; 1999; 94(4):433-40. PubMed ID: 10445998 [TBL] [Abstract][Full Text] [Related]
26. [Characterization of Neisseria meningitidis strains isolated from carriers in Cuba during 20 years]. Martínez Motas I; Sierra González G; Núñez Gutiérrez N; Izquierdo Pérez L; Climent Ruíz Y; Mirabal Sosa M Rev Cubana Med Trop; 2006; 58(2):124-33. PubMed ID: 23427430 [TBL] [Abstract][Full Text] [Related]
27. [Humoral immune response to the proteins of an antimeningococcal BC vaccine in a trial carried out in Antioquia, Colombia]. Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Blanco González R; Martínez Ruiz O; Martínez Fernández OM; Aguirre Muñoz CA Bol Oficina Sanit Panam; 1995 Apr; 118(4):285-94. PubMed ID: 7779283 [TBL] [Abstract][Full Text] [Related]
28. [Meningococcal disease and VA-MENGOC BC in minors less than 1 year of age. Cuba, 1983 to 1991]. Rico Cordeiro O; Jiménez Barreras R; Pereira Colls C Rev Cubana Med Trop; 1996; 48(1):34-9. PubMed ID: 9768267 [TBL] [Abstract][Full Text] [Related]
29. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign. Sevestre J; Hong E; Delbos V; Terrade A; Mallet E; Deghmane AE; Lemée L; Taha MK; Caron F Vaccine; 2017 Jul; 35(32):4029-4033. PubMed ID: 28624305 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322 [TBL] [Abstract][Full Text] [Related]
31. Comparison of long-term humoral memory development after immunisation against Neisseria meningitidis B or diphtheria toxoid. Cruz SC; Silva GP; Sampaio FJ; Souza SL; Dias AA; Milagres LG Vaccine; 2010 Oct; 28(42):6841-6. PubMed ID: 20719254 [TBL] [Abstract][Full Text] [Related]
32. Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application. Sotolongo F; Campa C; Casanueva V; Fajardo EM; Cuevas IE; González N MEDICC Rev; 2007 Oct; 9(1):16-22. PubMed ID: 21487356 [TBL] [Abstract][Full Text] [Related]
34. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Rappuoli R; Pizza M; Masignani V; Vadivelu K Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Arnold R; Galloway Y; McNicholas A; O'Hallahan J Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101 [TBL] [Abstract][Full Text] [Related]
36. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Pace D Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410 [TBL] [Abstract][Full Text] [Related]
37. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
38. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461 [TBL] [Abstract][Full Text] [Related]
39. [Humoral immune response to the capsular polysaccharide of Neisseria meningitidis serogroup C in an antimeningococcal BC vaccination trial in Antioquia, Colombia]. Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Martínez Ruiz O; Nerey MC; Camarasa MA; Bacallao Gallestey J Bol Oficina Sanit Panam; 1995 Apr; 118(4):295-301. PubMed ID: 7779284 [TBL] [Abstract][Full Text] [Related]
40. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]